# Mechanism of arbutin in metabolic dysfunction-associated fatty liver disease based on multi-omics research

**Authors:** Dapeng Yin, Jiacheng Cheng, Huili Cao, Xiaojuan Wang, Junhua He, Yikun Zhu, Jin Li

PMC · DOI: 10.1186/s40643-026-01032-5 · 2026-03-25

## TL;DR

This study shows that arbutin can help treat fatty liver disease by reducing liver damage and restoring gut microbiota balance.

## Contribution

The study reveals arbutin's anti-apoptotic and gut microbiota-regulating mechanisms in MAFLD treatment.

## Key findings

- Arbutin improved liver injury in MAFLD mice by inhibiting apoptosis via STAT3 signaling.
- Arbutin restored gut microbiota balance and altered fecal metabolite profiles in MAFLD mice.
- Arbutin's therapeutic effects were confirmed using in vivo and in vitro models of MAFLD.

## Abstract

Gut microbiota regulation is a key strategy for treating metabolic dysfunction-associated fatty liver disease (MAFLD). Arbutin (ARB) is a natural hydroquinone active agent with anti-inflammatory and antioxidant effects, as well as regulatory effects on the gut microbiota. However, its therapeutic effect on MAFLD and the responsible mechanisms remain unclear.

This study explored the therapeutic effect and mechanisms of ARB in MAFLD treatment.

High-fat diet (HFD)-fed mice served as the in vivo MAFLD model, and ARB treatment was given simultaneously. The extent of liver injury was assessed through histopathological staining. AML12 cells treated with free fatty acids served as the in vitro model. The effects of ARB were evaluated via oil red O staining and biochemical assays. Subsequently, we utilized bioinformatics techniques to predict the potential mechanisms and targets of ARB. The expression of liver apoptosis-related genes was detected using molecular biology techniques. Alterations in the gut microbiota were analyzed by 16S rRNA sequencing. Ultrahigh-performance liquid chromatography–high-resolution mass spectrometry was used to analyze the changes in fecal metabolite levels.

ARB treatment effectively improved liver injury in mice with MAFLD. Its mechanism was associated with anti-apoptotic effects mediated by signal transducer and activator of transcription 3. Meanwhile, ARB effectively reversed gut microbiota imbalance in mice with MAFLD and altered the composition of gut microbes and fecal metabolites.

ARB displayed potential effects in alleviating the pathology of MAFLD, exerting anti-apoptotic actions, and restoring the gut microbiota balance.

The online version contains supplementary material available at 10.1186/s40643-026-01032-5.

## Linked entities

- **Genes:** STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774]
- **Chemicals:** arbutin (PubChem CID 440936)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, Ctsb (cathepsin B) [NCBI Gene 13030] {aka APPM, CB}, Bcl2l1 (BCL2-like 1) [NCBI Gene 12048] {aka Bcl(X)L, Bcl-XL, Bcl2l, BclX, bcl-x, bcl2-L-1}, Bax (BCL2-associated X protein) [NCBI Gene 12028], Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, Bak1 (BCL2-antagonist/killer 1) [NCBI Gene 12018] {aka Bak, N-BAK1, N-Bak}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, Trf (transferrin) [NCBI Gene 22041] {aka Cd176, HP, Tf, Tfn, hpx}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, Slc17a5 (solute carrier family 17 (anion/sugar transporter), member 5) [NCBI Gene 235504] {aka 4631416G20Rik, 4732491M05, AST, ISSD, NSD, SD}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, Esr1 (estrogen receptor 1 (alpha)) [NCBI Gene 13982] {aka ER, ER-alpha, ERa, ERalpha, ESR, Estr}, Egfr (epidermal growth factor receptor) [NCBI Gene 13649] {aka 9030024J15Rik, Erbb, Errb1, Errp, Wa5, wa-2}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, Blnk (B cell linker) [NCBI Gene 17060] {aka BASH, Bca, Ly-57, Ly57, Lyw-57, SLP-65}, Ptgs2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 19225] {aka COX2, Cox-2, PES-2, PGHS-2, PHS II, PHS-2}, Dock2 (dedicator of cyto-kinesis 2) [NCBI Gene 94176] {aka CED-5, Hch, MBC}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Fn1 (fibronectin 1) [NCBI Gene 14268] {aka E330027I09, Fn, Fn-1}, Gpt (glutamic pyruvic transaminase, soluble) [NCBI Gene 76282] {aka 1300007J06Rik, 2310022B03Rik, ALT, ALT1, Gpt-1, Gpt1}, Gsk3b (glycogen synthase kinase 3 beta) [NCBI Gene 56637] {aka 7330414F15Rik, 8430431H08Rik, GSK-3, GSK-3beta, GSK3}
- **Diseases:** chronic inflammation (MESH:D007249), MAFLD (MESH:D005234), hypertrophy (MESH:D006984), liver disease (MESH:D008107), liver injury (MESH:D017093), weight loss (MESH:D015431), cirrhosis (MESH:D005355), hemolytic (MESH:D006461), dislocation (MESH:D004204), metabolic (MESH:D008659), hepatic injury (MESH:D056486), gut microbiota dysbiosis (MESH:D064806), cytotoxic (MESH:D064420), lipid metabolism disorder (MESH:D052439), non-alcoholic steatohepatitis (MESH:D005235), NAFLD (MESH:D065626), type 2 diabetes (MESH:D003924), obese (MESH:D009765), malnutrition (MESH:D044342), dyslipidemia (MESH:D050171), insulin resistance (MESH:D007333)
- **Chemicals:** sugar (MESH:D000073893), SCFAs (MESH:D005232), FFA (MESH:D005230), isopropanol (MESH:D019840), cortancyl (MESH:D011241), selenium (MESH:D012643), glucose (MESH:D005947), nitrogen (MESH:D009584), pioglitazone (MESH:D000077205), flavonoid (MESH:D005419), sucrose (MESH:D013395), EPA (MESH:D015118), OA (MESH:D019301), carbohydrate (MESH:D002241), hematoxylin (MESH:D006416), ARB (MESH:D001104), NO (MESH:D009614), penicillin (MESH:D010406), methanol (MESH:D000432), L (MESH:D007930), blood glucose (MESH:D001786), PA (MESH:D019308), bile acid (MESH:D001647), ceramides (MESH:D002518), hydroquinone (MESH:C031927), Oil red O (MESH:C011049), reactive oxygen species (MESH:D017382), paraffin (MESH:D010232), TRIzol (MESH:C411644), dexamethasone (MESH:D003907), TG (MESH:D014280), zirconium (MESH:D015040), isoflavone (MESH:D007529), Lipid (MESH:D008055), fat (MESH:D005223), xylene (MESH:D014992), paraformaldehyde (MESH:C003043), eosin (MESH:D004801), lecithin (MESH:D054709), alcohol (MESH:D000438), SDS (MESH:D012967), F12 (MESH:C007782), OCT (MESH:C051883), tribromoethanol (MESH:C062527), streptomycin (MESH:D013307), PVDF (MESH:C024865), H (MESH:D006859), Pio (MESH:D010389), cholesterol (MESH:D002784), DMEM (-), agarose (MESH:D012685)
- **Species:** Actinomycetota (actinobacteria, phylum) [taxon 201174], Paramuribaculum (genus) [taxon 2518497], Erysipelatoclostridium [taxon 1505663], Homo sapiens (human, species) [taxon 9606], Muribaculum (genus) [taxon 1918540], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Bacteroidota (Bacteroides-Cytophaga-Flexibacter group, phylum) [taxon 976], Mailhella (genus) [taxon 1981028], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** /6J — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_W797), AML12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0140), CCK-8 — Homo sapiens (Human), T-cell prolymphocytic leukemia, Cancer cell line (CVCL_5443)

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13018519/full.md

---
Source: https://tomesphere.com/paper/PMC13018519